Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H10N6.C4H6O6 |
| Molecular Weight | 340.292 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.NNC1=C2C=CC=CC2=C(NN)N=N1
InChI
InChIKey=HLSKIRWZKAEOEB-LREBCSMRSA-N
InChI=1S/C8H10N6.C4H6O6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;5-1(3(7)8)2(6)4(9)10/h1-4H,9-10H2,(H,11,13)(H,12,14);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of acute hypotension and hypertension on serum TSH concentrations in male rats. | 1979 Oct |
|
| [Rare liver damage caused by an antihypertensive and anti-arrhythmic agents]. | 1980 Apr 1 |
|
| [Liver lesions induced by dihydralazine and propranolol]. | 1985 |
|
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | 1996 Oct-Nov |
|
| Ketanserin for the treatment of preeclampsia. | 2001 |
|
| Influence of metabolic activation on the induction of micronuclei by antihypertensive drugs in L929 cells. | 2001 Feb |
|
| [Hypertensive disorders in pregnancy]. | 2001 Feb 15 |
|
| [Effect of Urapidil in antihypertensive therapy of preeclampsia on newborns]. | 2001 Sep |
|
| Immune-mediated drug-induced liver disease. | 2002 Aug |
|
| Drug-induced lupus as a cause of relapsing inflammatory disease after renal transplantation. | 2002 Aug |
|
| Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. | 2002 Dec 27 |
|
| The impact of maternal plasma volume expansion and antihypertensive treatment with intravenous dihydralazine on fetal and maternal hemodynamics during pre-eclampsia: a clinical, echo-Doppler and viscometric study. | 2004 Apr |
|
| [Determination of five components in compound hypotensive tablet by HPLC]. | 2004 Aug |
|
| Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. | 2004 Mar |
|
| Flow injection chemiluminescence determination of dihydralazine sulphate based on permanganate oxidation sensitized by rhodamine B. | 2004 Nov-Dec |
|
| Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. | 2004 Oct |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate based on hexacyanoferrate(III) oxidation sensitized by eosin Y. | 2004 Oct 8 |
|
| Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. | 2004 Sep |
|
| 3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4-a:4',3'-c]phthalazine. | 2004 Sep |
|
| Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. | 2004 Sep 21 |
|
| Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. | 2006 Aug |
|
| Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. | 2007 Jun |
|
| Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. | 2008 Jan |
|
| Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. | 2008 Jul |
|
| Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis. | 2008 Jun 2 |
|
| Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | 2009 |
|
| Hemodynamic, morphometric and autonomic patterns in hypertensive rats - Renin-Angiotensin system modulation. | 2010 |
|
| [Drugs during preeclampsia. Fetal risks and pharmacology]. | 2010 Apr |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system. | 2010 Jan |
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
85851-61-2
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY | |||
|
DTXSID70235125
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY | |||
|
56842459
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY | |||
|
J9CB6K1N70
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY | |||
|
SUB01703MIG
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY | |||
|
100000087505
Created by
admin on Sat Dec 16 05:15:42 GMT 2023 , Edited by admin on Sat Dec 16 05:15:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
